VEGFA and retinopathy of prematurity: This approach has been modified by the BEAT-ROP (Bevacizumab Eliminates the Angiogenic Threat—Retinopathy of Prematurity) study of 2011, which was the first randomised clinical trial to evaluate the efficacy of intravitreal monotherapy with an anti-VEGF drug (Bevacizumab) in the treatment of ROP.